CN102740877B - 对源自hsp65的肽-6有特异性的人源化抗体及其方法和用途 - Google Patents

对源自hsp65的肽-6有特异性的人源化抗体及其方法和用途 Download PDF

Info

Publication number
CN102740877B
CN102740877B CN201080050177.2A CN201080050177A CN102740877B CN 102740877 B CN102740877 B CN 102740877B CN 201080050177 A CN201080050177 A CN 201080050177A CN 102740877 B CN102740877 B CN 102740877B
Authority
CN
China
Prior art keywords
seq
variable region
antibody
humanized antibody
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080050177.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102740877A (zh
Inventor
雅各布·纳帕斯塔克
S·亚伊尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PROTAB Ltd
Original Assignee
PROTAB Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PROTAB Ltd filed Critical PROTAB Ltd
Publication of CN102740877A publication Critical patent/CN102740877A/zh
Application granted granted Critical
Publication of CN102740877B publication Critical patent/CN102740877B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080050177.2A 2009-09-06 2010-09-06 对源自hsp65的肽-6有特异性的人源化抗体及其方法和用途 Expired - Fee Related CN102740877B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24021809P 2009-09-06 2009-09-06
US61/240,218 2009-09-06
PCT/IL2010/000731 WO2011027349A1 (en) 2009-09-06 2010-09-06 Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof

Publications (2)

Publication Number Publication Date
CN102740877A CN102740877A (zh) 2012-10-17
CN102740877B true CN102740877B (zh) 2015-01-14

Family

ID=43648941

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080050177.2A Expired - Fee Related CN102740877B (zh) 2009-09-06 2010-09-06 对源自hsp65的肽-6有特异性的人源化抗体及其方法和用途

Country Status (12)

Country Link
US (3) US8680241B2 (enExample)
EP (2) EP2475383A4 (enExample)
JP (1) JP5781514B2 (enExample)
KR (1) KR101831229B1 (enExample)
CN (1) CN102740877B (enExample)
AU (1) AU2010290844B2 (enExample)
BR (1) BR112012004983A2 (enExample)
CA (1) CA2772567A1 (enExample)
IN (1) IN2012DN02869A (enExample)
MX (1) MX2012002768A (enExample)
RU (1) RU2596925C2 (enExample)
WO (1) WO2011027349A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2068889T (lt) 2006-08-10 2020-02-10 Roy C. Levitt Anakinra, naudojama bronchiolito obliteranso sindromo gydymui
DK3209684T3 (da) * 2014-10-24 2021-02-22 Hoffmann La Roche VH-VL-interdomænevinkelbaseret antistofhumanisering
WO2016116948A1 (en) 2015-01-22 2016-07-28 Ram Isanaka Peptide for treating inflammatory diseases
EP3320099B1 (en) * 2015-07-09 2023-09-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Lentiviral vector expressing membrane-anchored or secreted antibody
CN108883193A (zh) * 2016-03-31 2018-11-23 伊穆特丽克斯治疗股份有限公司 先兆子痫和有关障碍的体外治疗方法
WO2020025703A1 (en) * 2018-08-01 2020-02-06 Imcheck Therapeutics Sas Anti-btn3a antibodies and their use in treating cancer or infectious disorders
WO2025155809A2 (en) * 2024-01-18 2025-07-24 Nextcure, Inc. Compositions and methods for modulating vstm-1 mediated signal transduction
WO2025231127A1 (en) * 2024-05-02 2025-11-06 The Regents Of The University Of California Compositions and methods for intracellular antigen targeting with antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
US7488476B2 (en) * 1998-11-05 2009-02-10 Hadasit Medical Research Services & Development Ltd. B-cell epitope peptides of HSP 65, DNA encoding said peptides, antibodies directed against said peptides and the different uses thereof in the treatment of inflammatory and autoimmune diseases
CA2350340C (en) * 1998-11-05 2011-08-09 Hadasit Medical Research Services & Development Ltd. B-cell epitopes of hsp65 and uses thereof
WO2003057527A2 (en) * 2001-12-31 2003-07-17 L.A.S. Trust, Ein 02/6105365 Recreational vehicle
EP1619521A1 (en) 2004-07-22 2006-01-25 IEE INTERNATIONAL ELECTRONICS & ENGINEERING S.A. Capacitive transmitter electrode
CU23504A1 (es) * 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
DK1844074T3 (da) 2005-02-03 2013-07-15 Antitope Ltd Humane antistoffer og proteiner
CA2619654A1 (en) * 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
US20090221024A1 (en) 2006-03-02 2009-09-03 Antitope Limited T cell assays
US20080019979A1 (en) * 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
EP2138576A4 (en) 2007-03-16 2011-02-23 Kyowa Hakko Kirin Co Ltd ANTI-CLAUDIN-4 ANTIBODY
EP2500362A3 (en) * 2007-11-13 2012-10-24 Teva Biopharmaceuticals USA, Inc. Humanized antibodies against TL1A
CN102448990A (zh) 2009-03-30 2012-05-09 普罗塔布有限公司 腺苷酸环化酶相关蛋白(cap1)及其作为免疫调节靶标的应用
CA2841416A1 (en) * 2011-06-15 2012-12-20 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications

Also Published As

Publication number Publication date
AU2010290844B2 (en) 2015-04-09
CA2772567A1 (en) 2011-03-10
BR112012004983A2 (pt) 2021-02-23
RU2596925C2 (ru) 2016-09-10
US8680241B2 (en) 2014-03-25
JP5781514B2 (ja) 2015-09-24
US20120156201A1 (en) 2012-06-21
KR20120060224A (ko) 2012-06-11
MX2012002768A (es) 2012-06-28
CN102740877A (zh) 2012-10-17
RU2012106891A (ru) 2013-10-27
US20170218056A1 (en) 2017-08-03
WO2011027349A1 (en) 2011-03-10
IN2012DN02869A (enExample) 2015-07-24
EP2475383A4 (en) 2013-07-17
KR101831229B1 (ko) 2018-02-22
EP3366308A1 (en) 2018-08-29
JP2013503852A (ja) 2013-02-04
US20140170138A1 (en) 2014-06-19
EP2475383A1 (en) 2012-07-18
AU2010290844A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
US11365255B2 (en) PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
US11780923B2 (en) PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
CN102740877B (zh) 对源自hsp65的肽-6有特异性的人源化抗体及其方法和用途
EP3689909A1 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
US11345753B2 (en) TIM-3 antibody, antigen binding fragment thereof, and medicinal uses thereof
TW202146451A (zh) 抗人類cd19抗體
EP3858857A1 (en) An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
WO2022228183A1 (zh) 抗siglec15抗体及其制备方法和用途
WO2024160076A1 (zh) 针对人il-36r和/或人il-1r3的多种抗体及其用途
US20250320293A1 (en) Anti-trem2 single-domain antibody and use thereof
CN114269788A (zh) 一种能够与人4-1bb结合的分子及其应用
WO2019072274A1 (zh) 一种激动型4-1bb单克隆抗体
WO2019054460A1 (ja) 抗ｒａｍｐ２抗体
TW202542202A (zh) 抗體、抗原結合片段及其醫療用途
US20240166745A1 (en) Lag-3 and pd-1/lag-3-antibodies
HK40118644A (zh) 抗-tl1a抗体及其使用方法
HK1213910B (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150114

Termination date: 20200906

CF01 Termination of patent right due to non-payment of annual fee